NASDAQ:CNTN Hillstream Biopharma (CNTN) Stock Price, News & Analysis $3.19 0.00 (0.00%) As of 12:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock About Hillstream Biopharma Stock (NASDAQ:CNTN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hillstream Biopharma alerts:Sign Up Key Stats Today's Range$3.17▼$3.3150-Day Range$2.98▼$4.6652-Week Range$1.08▼$9.08Volume199,167 shsAverage Volume780,400 shsMarket Capitalization$180.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey. Read More Hillstream Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreCNTN MarketRank™: Hillstream Biopharma scored higher than 14% of companies evaluated by MarketBeat, and ranked 68th out of 75 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingHillstream Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageHillstream Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Hillstream Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Hillstream Biopharma is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hillstream Biopharma is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHillstream Biopharma has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.29% of the float of Hillstream Biopharma has been sold short.Short Interest Ratio / Days to CoverHillstream Biopharma has a short interest ratio ("days to cover") of 6.25.Change versus previous monthShort interest in Hillstream Biopharma has recently decreased by 7.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHillstream Biopharma does not currently pay a dividend.Dividend GrowthHillstream Biopharma does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.93 News SentimentHillstream Biopharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Hillstream Biopharma this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for CNTN on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows1 people have added Hillstream Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Hillstream Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders6.70% of the stock of Hillstream Biopharma is held by insiders.Percentage Held by Institutions1.16% of the stock of Hillstream Biopharma is held by institutions.Read more about Hillstream Biopharma's insider trading history. Receive CNTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hillstream Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTN Stock News HeadlinesHillstream Biopharma (CNTN) vs. Its Peers Financial AnalysisMay 12 at 3:37 AM | americanbankingnews.comFinancial Survey: Hillstream Biopharma (CNTN) and Its RivalsMay 6, 2026 | americanbankingnews.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 12 at 1:00 AM | Porter & Company (Ad)Canton Strategic Holdings, Inc. Presents Quarterly Canton Network Ecosystem UpdateApril 20, 2026 | prnewswire.comCanton Strategic Holdings Reports Full Year 2025 Financial and Operational ResultsMarch 31, 2026 | prnewswire.comSee More Headlines CNTN Stock Analysis - Frequently Asked Questions How have CNTN shares performed this year? Hillstream Biopharma's stock was trading at $4.66 on January 1st, 2026. Since then, CNTN stock has decreased by 30.0% and is now trading at $3.26. How were Hillstream Biopharma's earnings last quarter? Hillstream Biopharma Inc. (NASDAQ:CNTN) released its quarterly earnings results on Tuesday, March, 31st. The company reported $0.54 earnings per share for the quarter. How do I buy shares of Hillstream Biopharma? Shares of CNTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/31/2026Today5/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, CNTN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTN CIK1861657 WebN/A Phone(302) 743-2995FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.59% Return on Assets-27.05% Debt Debt-to-Equity RatioN/A Current Ratio5.29 Quick Ratio5.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.92 per share Price / Book0.29Miscellaneous Outstanding Shares56,660,000Free Float52,860,000Market Cap$181.60 million OptionableN/A Beta1.44 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CNTN) was last updated on 5/12/2026 by MarketBeat.com Staff. From Our PartnersBSEM: From OTC to Nasdaq Contender!BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited fi...Huge Alerts | SponsoredYale just did the math (you owe Washington $1,500)The Yale Budget Lab calculated that current U.S. trade policy is costing the average American household betwee...Priority Gold | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredIs $24 trillion about to move?Bloomberg reports that S-P Dow Jones Indices is considering rule changes that could fast-track SpaceX into the...The Oxford Club | SponsoredSpaceX Launches Strange 'Dark Energy' Across AmericaSpaceX is deploying a newly permitted energy technology - one that analyst Joel Litman calls 'Dark Energy' - t...Altimetry | SponsoredRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hillstream Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
